ARCHIVES

Ibrutinib Increases OS, PFS Versus Ofatumumab in Phase III

This article is from The Cancer Letter archive.

Vol. 37 No. 6 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

AGS-003 Immunotherapy Induces T Cell Responses in Phase II Trial

November 29, 2013

In Surprising Result, Survey Of Centers Finds Little “Crisis” In Clinical Research

September 29, 1995

Virus Working Group Suggests 14 Projects As Suitable For New Contract Proposals

March 1, 1974

In Brief: NSABP Proposal Selected for Tamoxifen Trials; NIH Building To Be Named After Silvio Conte

March 8, 1991

BCI Budget Chief Browning To Retire

January 12, 1979

Generic Paclitaxel Approval Withstands Court Challenge.

May 4, 2001